Autor: |
V, Chaudhry, M, Giuliani, B G, Petty, D, Lee, M, Seyedsadr, D, Hilt, D R, Cornblath |
Rok vydání: |
2000 |
Předmět: |
|
Zdroj: |
Musclenerve. 23(2) |
ISSN: |
0148-639X |
Popis: |
This phase I, double-blind, randomized, placebo-controlled study evaluated the safety of single and multiple (daily for 7 days) subcutaneous administrations of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy human volunteers at seven doses, ranging from 3 to 500 microg/kg/day. No serious or life-threatening adverse events occurred. The most frequently recorded adverse effects were mild injection-site pain, diarrhea, and elevation of liver function tests. No change in neurologic function was noted with these dosing regimens. We conclude that r-metHuNT3 is safe and well tolerated in the dosages used in this study. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|